Lomita

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• COPD1 trial
• Heart failure1 trial
• Obesity1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Not yet recruiting4 trials
• Recruiting2 trials
• Completed1 trial

Lead sponsor

• AstraZeneca6 trials
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics1 trial

Running trials

• Recruiting

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

  NCT07619118· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

  NCT07619131· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· Phase 3· AstraZeneca· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Heart failure1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

  NCT07400588· Phase 2· Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics· Source